886746-58-3 Usage
General Description
4,8-di(5-bromothiophene-2-yl)benzo[1,2-c:4,5-c']bis[1,2,5]thiadiazole is a complex chemical compound with a unique molecular structure. It consists of two 5-bromothiophene-2-yl groups attached to a benzo[1,2-c:4,5-c']bis[1,2,5]thiadiazole core. 4,8-di(5-bromothiophene-2-yl)benzo[1,2-c:4,5-c']bis[1,2,5]thiadiazole is widely used in organic electronics and is known for its high electron mobility and excellent photovoltaic properties. Its unique structure and properties make it a promising candidate for use in the development of new electronic materials, such as organic solar cells and light-emitting diodes. Additionally, the presence of bromine atoms in its structure also makes it a potential candidate for use in organic synthesis and drug development. Overall, 4,8-di(5-bromothiophene-2-yl)benzo[1,2-c:4,5-c']bis[1,2,5]thiadiazole is a versatile and important chemical compound with potential applications in various fields of science and technology.
Check Digit Verification of cas no
The CAS Registry Mumber 886746-58-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,7,4 and 6 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 886746-58:
(8*8)+(7*8)+(6*6)+(5*7)+(4*4)+(3*6)+(2*5)+(1*8)=243
243 % 10 = 3
So 886746-58-3 is a valid CAS Registry Number.
886746-58-3Relevant articles and documents
A high-contrast photoacoustic agent with near-infrared emission
Chen, Weijie,Ye, Fengying,Yin, Jun,Yang, Guang-Fu
, p. 223 - 247 (2021/07/26)
Benzobisthiadiazole as a typical electron acceptor, has been widely used to design fluorescent dyes and photoacoustic (PA) agents. With the strategy of constructing donor-acceptor-donor (D-A-D) type of electron characteristics, benzobisthiadiazole derivatives tend to behave stable in near-infrared absorption and emission, which is beneficial to PA imaging. In this chapter, two molecular design strategies are combined to improve the photoacoustic imaging effects of new PA contrast agent IR-1302 NPs, by installing strengthened conjugated bridges and electron donors. The nanoparticles exhibit high-contrast noninvasive photoacoustic imaging in tumor models with longer wavelength absorption and emission and show potential as a clinic contrast agent.
